NuPotential's NP-Reprog cell reprogramming platform is the basis for its isued foundation patent demonstrating that small molecule inhibition of epigenetic factors involved in single carbon metabolism can reprogram somatic cells to a pluripotent state. NuPotential has since built a robust patent family in support of  NP-Reprog, focusing on improving reprogramming efficiencies by identifying and developing novel and proprietary small molecule inhibitors (NP-Epidrugs) of epigenetic targets that limit cellular capacity for dedifferentiation. 

NP-Reprog does not rely on cell extracts, nuclear transfer, or exogenous , genomic integrating technologies that ca cause cancer.  Instead, NP-Epidrugs are used to selectively erase the epigenetic memory of mature adult cells (somatic cells), putting them into an embryonic-like (pluripotent) state from which they can potentially transform into any of the more than 200 types of cells in the human body.  The resulting reprogrammed cells are referred to as "NP-iPS" (induced pluripotent) cells.  These cells can then be developed into in vitro models of chronic diseases ("NP-Disease in a Dish") for drug discovery and personalized medicine applications and cell therapeutics.

NP-Reprog is leveraged by NuPotential's PIER epidrug discovery platform and the discovery of an epigenetic regulatory mechanism involved in epigenomic maintenance, or what NuPotential calls "Persistent Epigenetic Memory" (PEM).  NuPotential believes PEM is a major obstacle to realizing industry-compatable reprogramming efficiencies using industry preferred, non-transgenic reprogramming methods.  NuPotential is developing NP-Epidrugs to inhibit epigenetic targets within PEM, thus enabling NP-Reprog to overcome PEM and potentiate industry leading reprogramming efficiencies and plurigene expression maintenance over continuous cell expansions.  

NP-Reprog has several built-in advantages including:

• An industry prescribed, small molecule focused reprogramming method.
• Validating in vitro and in vivo studies; the company's reprogrammed cell lines demonstrate increased embryoid body and colony formation, re-expression of pluripotency markers, teratoma formation, and improved blostocyst development after SCNT.
• NP-iPS cell lines developed using NP-Reprog demonstrate clear improvements in differentiation capacity over specified, approved human stem cell lines.  
• PIER and NP-Epidrug driven technology.
• Stong IP support.